Bristol-Myers Squibb Company (FRA:BRM)
Germany
· Delayed Price · Currency is EUR 39.91
-0.09 (-0.23%)
At close: Jun 27, 2025, 10:00 PM CET
FRA:BRM Revenue
Bristol-Myers Squibb Company had revenue of $11.20B USD in the quarter ending March 31, 2025, a decrease of -5.60%. This brings the company's revenue in the last twelve months to $47.64B, up 4.62% year-over-year. In the year 2024, Bristol-Myers Squibb Company had annual revenue of $48.30B with 7.32% growth.
Revenue (ttm)
$47.64B
Revenue Growth
+4.62%
P/S Ratio
1.83
Revenue / Employee
$1.40M
Employees
34,100
Market Cap
80.51B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 48.30B | 3.29B | 7.32% |
| Dec 31, 2023 | 45.01B | -1.15B | -2.50% |
| Dec 31, 2022 | 46.16B | -226.00M | -0.49% |
| Dec 31, 2021 | 46.39B | 3.87B | 9.09% |
| Dec 31, 2020 | 42.52B | 16.37B | 62.62% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| SAP SE | 35.15B |
| Siemens Aktiengesellschaft | 77.82B |
| Deutsche Telekom AG | 120.25B |
| Allianz SE | 109.03B |
| Rheinmetall AG | 10.48B |
| Siemens Energy AG | 37.44B |
| Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 61.84B |
| Siemens Healthineers AG | 23.14B |
Bristol-Myers Squibb Company News
- 4 days ago - Cigna sues Bristol Myers for alleged monopoly over blockbuster cancer drug - CNBC
- 4 days ago - Cigna files antitrust case against Bristol Myers over Pomalyst sales - Seeking Alpha
- 11 days ago - Bristol Myers Squibb Announces Dividend - Wallstreet:Online
- 12 days ago - Bristol Myers Squibb Presents First Data from the Marginal Zone Lymphoma Cohort of the Transcend FL Trial Demonstrating Deep and Durable Responses with Breyanzi (lisocabtagene maraleucel) - Wallstreet:Online
- 16 days ago - Bristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD Agents and BCL6 Ligand-Directed Degrader at EHA 2025 - Wallstreet:Online
- 17 days ago - Bristol-Myers Squibb Company (BMY) Presents at Goldman Sachs 46th Annual Global Healthcare Conference (Transcript) - Seeking Alpha
- 17 days ago - Bristol Myers Squibb Presents Late-Breaking Data from Pivotal Phase 3 POETYK PsA-1 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis - Wallstreet:Online
- 20 days ago - Notable healthcare headlines for the week: Bristol Myers Squibb, Novo Nordisk and Sanofi in focus - Seeking Alpha